ClinicalTrials.gg
RecruitingNCT07203001Updated Nov 9, 2026

A Phase II Trial to Evaluate the Clinical Efficacy, Safety and Tolerability of MAS825 in Pediatric and Adult Participants With Still's Disease

A Phase 2 interventional study of MAS825 in Still´s Disease, sponsored by Novartis Pharmaceuticals. Recruiting at 24 sites in 8 countries. Open to participants aged 1 Year and older. Per ClinicalTrials.gov, last updated 2026-11-09.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Nov 2025; still recruiting 1 year later.
Updated Nov 9, 20262 sites added1 site removedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
30
Allocation
Not applicable
Ages
1 Year and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 18 studies in Arthritis, Juvenile by Novartis — 6 open to participants now, 6 under way, none of them phase 3. Arthritis, Juvenile · Novartis.

Planned enrollment
8th of 12
30 · median 43
Started
2025
with 5 others
Phase 2
Only one
of the 18
Registered
15th of 18
by date

Among the 18 studies in Arthritis, Juvenile by Novartis, this one is the 8th largest by planned enrollment of the 12 interventional ones that give a count, is one of 6 that started in 2025, is the only one in phase 2, and was the 15th registered.

Arthritis, Juvenile

366 studies on the registry are indexed under Arthritis, Juvenile; 101 are open to participants now.

Browse Arthritis, Juvenile studies →

Open to participants now

6 of the 18 studies in Arthritis, Juvenile by Novartis are open now, in 10 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

Who these studies take

Of the 68 Arthritis, Juvenile studies recruiting now, 13 (19%) set no upper age limit and 49 (72%) stop at 75 or younger; 64 take children under 18; 11 take healthy volunteers.

This study: 1 Year and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies in Arthritis, Juvenile by Novartis, or all of them as a file.
02

Study summary

The study is a phase II trial designed to evaluate the clinical efficacy, safety, and tolerability of MAS825 (arumakimig) in pediatric and adult participants with Still's disease

Read the detailed description

This is a multicenter, open-label, single-arm study to assess clinical efficacy, safety and tolerability of MAS825 in participants (both pediatric and adult) with Still's disease who have had inadequate response to IL-1 and/or IL-6 or other available therapies. Participants with associated lung disease and/or macrophage activation syndrome may also be included.

This study has three periods (Screening, Treatment Period 1, and Treatment Period 2) and a total duration of approximately 16 months.

03

Conditions studied

  • Still´s Disease

Browse trials for

Keywords

  • Still´s disease
  • pediatric
  • adult
  • sJIA
  • AOSD
  • Systemic Juvenile Idiopathic Arthritis
  • Adult Onset Still s disease
  • rheumatology
  • MAS825
  • arumakimig
04

Who can participate

Ages eligible
1 Year and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥ 1 with a diagnosis of Still's Disease
  • Active diseases defined as:
  • CRP or ferritin levels greater than , and any of:

    • Fever ≥ 38°C attributed to Still's Disease activity and documented for a number of days prior to Day 1 or
    • Rash attributed to Still's Disease activity or
    • Musculoskeletal involvement: arthritis in a number of joints per ACP criteria for active joint or
    • Serositis or
    • Macrophage activation syndrome activity as defined by ferritin levels and at least one of: count, a biomarker or fibrinogen levels attributed to Still's Disease activity by the investigator
  • Intolerance or inadequate response to available biologic therapy

Exclusion criteria

Exclusion Criteria:

  • Patients out of weight range
  • Ongoing or previous treatment with immunomodulatory drugs

    • A limited number of Still's Disease patients that have previously received MAS825 through a managed access program are permitted on the study
  • dose exceeding a set limit
  • Any conditions or significant medical problems which places the patient at unacceptable risk for MAS825 therapy

    • Still's disease patients with evidence of macrophage activation syndrome are permitted in the study
    • Still's Disease patients with evidence of interstitial lung disease including those requiring supplemental oxygen therapy are permitted in the study
  • History of ongoing, chronic or possibly recurrent infection (e.g. , TB, , ) and/or symptoms and signs of active bacterial, fungal or viral infections
  • within a set time prior to MAS825 treatment. Live vaccines are prohibited up to several months following the last dose
  • History of of any organ system, including post-transplant lymphoproliferative disorder, treated or untreated, within a number of years, regardless of whether there is evidence of local recurrence and
  • History of to any of the study drugs or to drugs of similar chemical classes or to any of the
  • Pregnant or breastfeeding women
  • Women of who do not agree to comply with required use

Other protocol-defined inclusion/exclusion criteria may apply.

Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    MAS825

    Experimental drug

    Drug: MAS825

Interventions

  • DrugMAS825

    Experimental drug

    Also known as: Arumakimig

06

What researchers measure

Primary outcomes

  1. Number of participants with clinical response based on one set of response criteria

    Established measure for efficacy of treatments in the rheumatologic conditions taking into account self-assessment, function and survival.

    Time frame: Day 85

Secondary outcomes

  1. Number of participants with clinical response based on another set of response criteria

    Established measure for efficacy of treatments in the rheumatologic conditions taking into account self-assessment, function and survival.

    Time frame: Day 85

  2. Response based on a biomarker level

    To evaluate the efficacy of MAS825 in reducing clinical disease activity

    Time frame: Baseline, Day 85

  3. Change in physician assessment based on laboratory features of MAS825

    To assess the effect of MAS825 on macrophage activation syndrome

    Time frame: Baseline, 15 months

  4. Change from baseline in Glucocorticoid (GC) dose

    To evaluate the efficacy of MAS825 as a glucocorticoid-sparing agent

    Time frame: Baseline, Day 85, Month 6, Month 12

  5. Change from baseline in patient/parent assessment of physical function as assessed by Quality of Life instrument

    To evaluate the efficacy of MAS825 in improving participant's quality of life

    Time frame: Baseline, Day 85

  6. Clinically inactive disease whilst on non-treatment dose corticosteroid at any time during the study

    The number of participants with inactive disease will be assessed. Disease activity will be evaluated by the investigator based on physical examination and laboratory parameters. Inactive disease is defined according to protocol-specific criteria, which include clinical signs, laboratory values, and physician assessment.

    Time frame: 15 months

07

Study locations

20 of 24 sites recruiting
  • Cincinnati Childrens Hospital
    Cincinnati, Ohio 45229, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Legacy Emanuel Research Hosp Portland
    Portland, Oregon 97232, United States
    Recruiting
    • Brenna Bogle · Contactbbogle@lhs.org · +1 503 413 5447
    • Daniel Joseph Kingsbury · Principal investigator
  • University of Utah
    Salt Lake City, Utah 84113, United States
    Recruiting
  • Novartis Investigative Site
    Toronto, Ontario M5G 1X8, Canada
    Recruiting
  • Novartis Investigative Site
    Montreal, Quebec H3T 1C5, Canada
    Withdrawn

    Not enrolling at this site — choose another above.

  • Novartis Investigative Site
    Montreal, Quebec H4A 3J1, Canada
    Withdrawn

    Not enrolling at this site — choose another above.

  • Novartis Investigative Site
    Bordeaux, 33076, France
    Recruiting
  • Novartis Investigative Site
    Bron, 69677, France
    Recruiting
  • Novartis Investigative Site
    Le Kremlin-Bicêtre, 94275, France
    Recruiting
  • Novartis Investigative Site
    Lille, 59037, France
    Recruiting
  • Novartis Investigative Site
    Paris, 75015, France
    Recruiting
  • Novartis Investigative Site
    Paris, 75970, France
    Recruiting
  • Novartis Investigative Site
    Sankt Augustin, North Rhine-Westphalia 53757, Germany
    Recruiting
  • Novartis Investigative Site
    Heidelberg, 69120, Germany
    Recruiting
  • Novartis Investigative Site
    Münster, 48149, Germany
    Recruiting
  • Novartis Investigative Site
    Florence, FI 50139, Italy
    Recruiting
  • Novartis Investigative Site
    Genova, GE 16147, Italy
    Recruiting
  • Novartis Investigative Site
    Roma, RM 00165, Italy
    Recruiting
  • Novartis Investigative Site
    Utrecht, 3584 CX, Netherlands
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Novartis Investigative Site
    Esplugues, Barcelona 08950, Spain
    Recruiting
  • Novartis Investigative Site
    Madrid, 28046, Spain
    Recruiting
  • Novartis Investigative Site
    Valencia, 46026, Spain
    Recruiting
  • Novartis Investigative Site
    Istanbul, Fatih 34098, Turkey (Türkiye)
    Recruiting
  • Novartis Investigative Site
    Ankara, Sihhiye Altindag 06230, Turkey (Türkiye)
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com.

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Nov 2025 (actual). Primary completion is estimated for Apr 2027, 17 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 9, 2025
First posted
Oct 2, 2025
StartActual
Nov 3, 2025
Primary completionEst.
Apr 22, 2027
CompletionEst.
May 17, 2028
Last update
Nov 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
2 sites added, 1 site removed
Show 2 added (1 Turkey (Türkiye), 1 Canada)
  • Novartis Investigative Site · Ankara, Turkey (Türkiye)
  • Novartis Investigative Site · Toronto, Canada
Show 1 removed
  • Novartis Investigative Site · Ankara, Turkey (Türkiye)
across 2 updates, Sep 25, 2026 – Nov 9, 2026
Show all 2 updates
  1. Nov 9, 2026
    1 site added
    Show site
    • Novartis Investigative Site · Toronto, Canada
    + 1 other change: verification date
  2. Sep 25, 2026
    1 site added, 1 site removed
    Show site
    • Novartis Investigative Site · Ankara, Turkey (Türkiye)
    Show 1 removed
    • Novartis Investigative Site · Ankara, Turkey (Türkiye)

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07203001
Responsible party
Sponsor
First posted
Oct 2, 2025
Start date
Nov 3, 2025
Primary completion
Apr 22, 2027 (estimated)
Completion
May 17, 2028 (estimated)
Last update
Nov 9, 2026

Study contacts

Novartis Pharmaceuticals
Contact
novartis.email@novartis.com
1-888-669-6682
Novartis Pharmaceuticals
Contact
+41613241111

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Arumakimig

Start the discussion